Compare Adaptive Biotechnologies Corp (ADPT) vs VanEck Gold Miners ETF (GDX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs VanEck Gold Miners ETF — how do they compare? Adaptive Biotechnologies Corp trades at $19.89 (market cap $3.33B), while VanEck Gold Miners ETF trades at $73.4. The key difference: Adaptive Biotechnologies Corp is trading nearer its 52-week high, VanEck Gold Miners ETF nearer its low. Which is the better fit depends on your goals.
| ADPT | GDX | |
|---|---|---|
Market Cap | $3.33B | — |
Sector | Health | — |
52-Week High | $22.37 | $115.84 |
52-Week Low | $10.24 | $50.79 |
Enterprise Value | $3.19B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
GDX trades at $78.74, up 0.4% with bearish technical signals from moving averages but neutral oscillators. The ETF faces mixed sentiment as gold miners navigate volatile commodity markets, though some analysts highlight attractive valuations and strong fundamentals. Recent additions like Aya Gold & Silver to the ETF portfolio signal ongoing portfolio optimization.
The outlook remains cautious with technical resistance at $80-$83, while fundamental support comes from record free cash flow yields and discounted multiples. Key risks include gold price volatility and energy cost pressures, but central bank demand and portfolio diversification benefits provide long-term tailwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About VanEck Gold Miners ETF
The fund normally invests at least 80% of its total assets in common stocks and depositary receipts of companies involved in the gold mining industry. The index is a modified market-capitalization weighted index primarily comprised of publicly traded companies involved in the mining for gold and silver. The fund is non-diversified.
Read more on GDX →
